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Abstract. Dipeptidyl peptidase IV (DPP IV) is a serine peptidase which has been suggested to play a role 
in the pathogenesis of rheumatoid arthritis, but its mediator actions have not been well investigated in pa-
tients with spondyloarthritides. The purpose of this study was to investigate clinical relevance of changes 
in serum DPP IV activity and concentration in these diseases. Serum DPP IV activity was significantly 
decreased in patients with spondyloarthritides and rheumatoid arthritis compared to the control group, 
while DPP IV concentration was increased. Among spondyloarthritides patients, DPP IV concentration 
was decreased in patients with reactive arthritis. No difference was observed in DPP IV activity or concentra-
tion between spondyloarthritides and rheumatoid arthritis, as well as between patients with clinically active 
disease and those in remission. Our results suggest that DPP IV could not be used as a specific serum marker, 
but could be potentially used as a non-specific inflammatory marker. (doi: 10.5562/cca1863)  
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INTRODUCTION 
Spondyloarthritides (SpA) and rheumatoid arthritis 
(RA) are autoimmune inflammatory diseases character-
ized by chronic inflammation of joints leading to their 
progressive and irreversible destruction.1 SpA are a 
heterogeneous group of related diseases, including pso-
riatic arthritis (PsA), ankylosing spondylitis (AS) and 
reactive arthritis (ReA) which commonly share similar 
epidemiological, clinical and radiological features, as 
well as pathogenetic mechanisms.2–6 Inflammatory 
processes that are associated with rheumatic diseases 
are regulated by exogenous and endogenous factors, 
including cytokines, chemokines and peptidases. Cyto-
kines and chemokines, particularly  stromal derived 
factor-1 (SDF-1) and tumour necrosis factor  
(TNF), are implicated in each phase of the pathogene-
sis by promoting autoimmunity and by maintaining 
chronic synovitis and tissue destruction.7 Furthermore, it 
has been suggested that cell surface peptidases play an 
important role in the activation or inactivation of media-
tors involved in the occurrence and perpetuance of in-
flammatory processes.8  
Dipeptidyl peptidase IV (DPP IV; EC 3.4.14.5), 
known as CD26 molecule is a widely expressed multi-
functional glycoprotein present both on the cell surface 
of various tissues and as a soluble form in plasma and 
other biological fluids. As a serine protease, DPP IV 
cleaves the N-terminal dipeptides from proteins having 
either proline or alanine at the penultimate position. 
Numerous biologically active polypeptides like hor-
mones, cytokines, and chemokines share this sequence 
and are potential substrates. Experimental and clinical 
data indicate an important role of DPP IV in degrada-
tion of SDF-1, TNFα and many other inflammatory 
molecules.9 Furthermore, several studies point out the 
involvement of CD26 in T lymphocyte activation and 
proliferation which results in the change of the Th1/Th2 
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balance towards a Th1-like reaction.10 Therefore, DPP 
IV could be implicated in the modulation of the immune 
response. 
In rheumatic diseases, as chronic inflammatory 
immune-mediated disorders, DPP IV as a protease 
and/or CD26 antigen may have a dual role: on the one 
hand stimulating cellular immunity, and on the other 
modulating chemokine functions. A number of studies 
have shown that, in RA patients, DPP IV activity or 
CD26 antigen levels in serum as well as in synovial 
membrane were changed in comparison to controls, but 
there is no such data for SpA patients. DPP IV inhibi-
tors have been shown to suppress migration of T lym-
phocyte subpopulation into the inflamed tissue, as well 
as suppressing T cell DNA synthesis and production of 
TNFα and interleukin-11. Although there is a lot of 
evidence about the importance of DPP IV in immuno-
modulation, its precise role in the ethiopathogenesis of 
rheumatic diseases is not entirely clear. 
Based on the described potential role of DPP IV in 
the modulation of immune response, we hypothesized 
that serum DPP IV activity and concentration are altered 
in various rheumatic diseases, including PsA, AS and 
ReA. The aim of this study was to estimate the clinical 
relevance of changes in serum DPP IV activity and 
concentration, which could be connected to disease 
activity and might therefore be useful as a distinguish-
ing diagnostic marker among SpA diseases. 
MATERIALS AND METHODS 
Patients  
Patients included in this study were recruited at the 
Department of Rheumathology, Thalassotherapy Hospi-
tal, School of Medicine, University of Rijeka, Croatia. 
The study was performed according to the principals of 
the Declaration of Helsinki and was approved by the 
Ethics Committee for Medical Research, School of 
Medicine, University of Rijeka. All involved patients 
signed the informed consent. The study included 239 
patients with different categories of inflammatory arthri-
tis and 65 healthy controls. Clinical characteristics and 
demographic data which included age, sex and disease 
duration, as well as blood samples, were collected from 
each of these patients and presented in the Table I. Ac-
cording to the clinical presentation and laboratory data, 
patients were divided into two groups: RA patients and 
SpA patients who include PsA, AS and ReA patients. 
Furthermore, patients in each group were divided into 
two subgroups depending on the disease activity. 
 
Patients with SpA 
The study included 180 SpA patients who fulfilled the 
European Spondylarthropaty Study Group criteria for 
the disease.11 Among SpA patients 98 had PsA, 52 had 
AS and 30 had ReA. The classification of PsA patients 
was based on the presence of an inflammatory articular 
Table 1. Demographic and clinical characteristics of patients with spondyloarthritides and rheumatoid arthritis 
Diagnosis 
PsA AS ReA RA 
A R A R A R A R 
Number 48 50 31 21 19 11 29 30 


















Male:female ratio 22 :26 18 :32 25 :6 5 :16 7 :12 4 :7 7 :22 3 :27 
Swollen joint count 39(a)/6(b)/3(c) 49(a)/0(b)/1(c) – – 15(a)/1(b)/3(c) 11(a)/0(b)/0(c) 8(a)/11(b)/10(c) 28(a)/2(b)/0(c)
Tender joint count 17(a)/7(b)/24(c) 50(a)/0(b)/0(c) – – 11(a)/2(b)/6(c) 11(a)/0(b)/0(c) 2(a)/8(b)/19(c) 25(a)/4(b)/1(c)















Psoriasis (positive) 29 20 – – – – – – 
Schober’s test 
median (range) 
– – 3.0 (1.0–6.0) 
4.0 







(3.9–3.9) – – – – 
Peripheral arthritis / % – – 29.0 47.6 – – – – 
Sacroileitis / % – – – – 47.3 54.5 – – 
PsA, psoriatic arthritis; AS, ankylosing spondylitis; ReA, reactive arthritis; RA, rheumatoid arthritis; A, active; R, remission;
DAS 28, disease activity score 28; BASDAI, bath ankylosing spondylitis disease activity index. 
(a) Number of joints: < 4. 
(b) Number of joints: 4–8. 
(c) Number of joints: > 8. 
(d) Statistically significantly increased compared to remission, p  0.050. 
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disease, according to the Moll and Wright criteria,12 and 
psoriasis was confirmed clinically by the dermatologist. 
The disease activity was defined by the presence of 
swollen and tender joints together with erythrocyte 
sedimentation rate (ESR) and C-reactive protein con-
centration (CRP) as laboratory parameters of inflamma-
tion. The clinical activity of AS patients was evaluated 
using the Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) together with ESR and CRP, accord-
ing to The Assessment in Ankylosing Spondylitis Crite-
ria for AS.13 In these patients, early morning stiffness, 
Schober’s test, sagital indices for each part of the spine 
and HLA-B27 test were also evaluated. The disease 
activity in ReA patients was assessed equally as in PsA 
patients. In addition, swollen and tender joints, 
sacroiliitis and extra-articular manifestations (uveitis) 
were also evaluated in those patients. 
 
Patients with RA 
The study group included 59 RA patients diagnosed 
according to the American College of Rheumatology 
criteria.14,15 For each patient, 28-joint disease activity 
score (DAS 28) was calculated using swollen joint 
count (0–28), tender joint count (0–28) and ESR. 
Rheumatoid factor, CRP values and early morning 
stiffness were also recorded. According to the DAS 28, 
patients were classified as those with active disease 
and those in remission (Table 1). Joint counts  




The control group consisted of 65 healthy donors (32 
males and 33 females; mean age 42 ± 12 years) without 
symptoms of inflammatory joint disease or any other 
inflammatory conditions.  
 
Blood Samples 
Blood samples were obtained at the initial and/or fol-
low up visits, collected in dry tubes and centrifuged for 
12 minutes at 4000 rpm. Serum aliquots were immedi-
ately frozen at –80 ºC until analysis and used for the 
assessment of laboratory parameters, DPP IV activity 
and concentration. Laboratory parameters included 
ESR, CRP, imunoglobulin (Ig) A, IgG and IgM levels, 
erythrocytes, leucocytes, platelet, total iron binding 
capacity, total proteins, globulin fractions and albumin 
concentration.  
 
DPP IV Activity Assay 
Serum DPP IV enzyme activity was measured by a 
substrate conversion assay according to the protocol of 
Kreisel et al.16 DPP IV activity was determined 
spectrofotometrically by measuring the release of 4-
nitroaniline from an assay mixture containing 0.1 M 
Tris HCl buffer (pH = 8), chromogenic substrate Gly-
Pro-p-nitroanilide (Sigma Chemical, Steinheim, Germa-
ny) and enzyme in a total volume of 0.20 mL. After 30 
min incubation at 37 C, the reaction was stopped by 
addition of 0.8 mL of sodium acetate buffer (c = 1 mol 
dm–3, pH = 4.5). Absorbance was measured at λ = 405 
nm using a Varian Cary 100 UV/Vis spectrophotometer 
(Cary, NC, USA). All reactions were performed in du-
plicate. Enzyme activities were expressed as interna-
tional units per liter of serum. One unit corresponds to 
the hydrolysis of 1 mol of substrate per minute under 
assay conditions.  
 
Serum DPP IV immunodetection 
The measurement of DPP IV serum concentrations in 
patients with PsA, AS, ReA and RA was assessed by 
sandwich enzyme-linked immunosorbent assay ("Duo 
set" ELISA kit – DY1180, R&D Systems, UK) accord-
ing to the manufacturer's instructions. A microplate 
reader Bio-Tek (EL808, USA) was used to measure 
absorbance at λ = 450 nm. A wavelength correction was 
performed at λ = 570 nm.  
 
Statistical Analysis 
The collected data were statistically evaluated using the 
data analysis software system STATISTICA, version 
8.0. (StatSoft, Inc. Tulsa, USA). All data are reported as 
median and range, except where otherwise indicated. To 
test the differences between analyzed parameters, the 
Kruskal-Wallis and Mann-Whitney U test were used. 
Qualitative data were analysed using chi-square test. 
Spearman’s test was used to calculate correlation, as 
indicated in the text. P values less than 0.050 were con-
sidered to be statistically significantly different. 
 
RESULTS 
Patients’ Demographic and Clinical Characteristics  
Demographic and clinical characteristics of SpA and 
RA patients with active disease and those in remission 
are reported in Table 1. Pairwise test showed that both 
groups of RA patients were older compared to the pa-
tients with AS and ReA and to the controls (42 ± 12 
years). However, in the SpA group, PsA and ReA pa-
tients were older in comparison with AS. 
The proportion of female patients in both RA 
groups was statistically significantly higher, whereas in 
AS groups the proportion of male patients was statisti-
cally significantly higher. In other groups, chi-square 
test did not show statistically significant difference 
between male and female distribution.  
Among RA patients, 53 tested were positive for 
rheumatoid factor, 27 with active disease and 26 in 
remission. At the time of evaluation, psoriatic skin man-
ifestations were observed in 60.4 % active PsA patients 
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and 40.0 % of those in remission, while psoriasis mean 
duration was 19 ± 13 years in the PsA group. For each 
AS patient, spinal flexibility was measured by Schober’s 
test (Table 1) and by indices of sagital movement for 
cervical, thoracal and lumbosacral segment of the spine. 
Median of indices for active AS patients was 12.0 (2.0 –
15.0), 4.0 (1.0 – 6.0) and 5.0 (2.0 – 10.0) and for those in 
remission 13.0 (4.0 – 16.0), 6.0 (3.0 – 8.0) and 7.0 (1.0 –
10.0), respectively. Furthermore, extra-articular mani-
festations were present in 11 ReA patients and 17 of 
them had anterior uveitis positive for Chlamydia tra-
chomatis. 
All determined laboratory parameters are summa-
rized in Table 2. Serum CRP and ESR values of RA, 
PsA and AS patients who showed active disease symp-
toms were statistically significantly increased in com-
parison to those in remission, unlike ReA patients. In 
RA and ReA group serum CRP level correlated statisti-
cally significantly with DAS 28 (Spearman’s test: r = 
0.58; r = 0.35, p < 0.050). Finally, we did not observe 
any significant differences among other laboratory pa-
rameters between patients with active disease and those 
in remission in SpA or RA groups. 
 
Serum DPP IV Activity and Concentration 
Circulating DPP IV activity was significantly decreased 
in SpA (median: 36.3 IU L–1; range: 8.0 – 90.7) and RA 
patients (median: 33.6 IU L–1; range 12.1 – 78.6) com-
pared to the control group (median: 45.8 IU L–1; range: 
36.8 – 79.0) (Figure 1a). No difference was observed in 
serum DPP IV activity between SpA and RA patients 
(Figure 1a). The immunodetection of DPP IV in serum 
did not demonstrate a significant difference between 
DPP IV concentration in SpA (median 220.6 ng mL–1; 
range: 107.2 – 445.1) and RA (median 230.1 ng mL–1; 
range: 114.2 – 409.2) patients, but a significant differ-
ence was observed in comparison to the control group 
(median 164.9 ng mL–1; range 114.4 – 315.3) for both 
SpA and RA (Figure 1b). 
Among SpA patients, there was no statistically 
significant difference between serum DPP IV activi-
ties in each group. DPP IV activity in PsA (median: 
35.8 IU L–1; range: 8.0 – 90.7), AS (median: 37.1 IU L–1; 
range: 12.2 – 88.1) and ReA (median: 38.4 IU L–1; 
range: 16.0 – 69.1) patients was statistically signifi-
cantly increased compared to the control group (Fig-
ure 2a). Concentration of DPP IV in PsA (median: 
245.9 ng mL–1; range: 139.3 – 418.3) and AS (median: 
242.1 ng mL–1; range: 107.2 – 445.1) patients was statis-
tically significantly increased in comparison to ReA 
(median: 182.0 ng mL–1; range: 108.3 – 234.9) and to 
the control group (Figure 2b).  
No statistically significant difference of serum 
DPP IV activity or concentration was observed between 
patients with clinically active disease and those in re-
mission (Table 3) in RA or SpA groups. There was no 
statistically significant correlation between DPP IV 
activity or concentration and laboratory parameters such 
as CRP, as well as disease activity indices DAS 28 or 
BASDAI, except for ReA group where DPP IV activity 
correlated positively with CRP (Spearman’s test: r = 
0.52, p < 0.050). 
 
DISCUSSION 
The pathophysiology of SpA and RA is not completely 
understood, but it is believed that the genetic predisposi-
tion, environmental factors and immune response,  
including inflammatory mediators mainly produced  
by activated T lymphocytes and macrophages, partici-
pate in complex mechanisms at systemic and local level 
and lead to disease development. Both diseases are 
chronic inflammatory autoimmune disorders and better 
monitoring of their progression, evaluation of disease 
activity and monitoring of therapeutic efficiency is 
indeed necessary. The diagnostic algorithm of SpA 
diseases is complex and based on clinical signs, labora-
tory parameters and radiographic findings. Therefore, 
the diagnosis is often delayed up to eight years from 
symptom onset.17 
According to our results and previously published 
data, laboratory abnormalities in SpA patients are non-
Table 3. Influence of disease activity on serum dipeptidyl 
peptidase IV (DPP IV) activity (z / IU L–1) and mass concen-





z(DPP IV) / 
IU L–1 














































Values are expressed as median (range). PsA, psoriatic arthri-
tis; AS, ankylosing spondylitis; ReA, reactive arthritis; RA, 
rheumatoid arthritis; A, active; R, remission. 
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specific and not as useful as the clinical presentation for 
diagnosis of specific disease. The present results show 
that patients with active SpA have increased CRP and 
ESR values, as well as patients with active RA. Since 
CRP and ESR are the two most commonly used clinical 
markers nowadays and show very low sensitivity and 
specificity,17 we investigated whether DPP IV could be 
used as a novel distinguishing and/or disease activity 
SpA marker.  
As far as we are aware, the present study is the 
first to demonstrate changed serum DPP IV activity and 
antigen level in adult patients with SpA. Our results 
revealed a decrease in serum DPP IV activity in patients 
with SpA, as well as those with RA, compared to the 
control group. Our findings are in agreement with the 
findings of Busso et al.,18 who also showed a decrease 
in DPP IV activity in RA patients. Since we observed 
no statistically significant difference in serum DPP IV 
activity and concentration between patients with SpA 
and RA, it can be concluded that this molecule could 
not be used as a specific differentiating marker. Moreo-
ver, our results showed no statistically significant dif-
ference in serum DPP IV activity among SpA groups of 
patients. Therefore, it seems that serum DPP IV activity 
could not be used as a specific serum marker within 
SpA diseases. 
DPP IV is predominantly present in a soluble form 
in blood and other body fluids and also as an antigen on 
the membrane of T lymphocytes.19 The precise origin 
and the physiological role of soluble DPP IV in plasma 
Figure 2. Serum dipeptidyl peptidase IV (DPP IV) activity (a)
and concentration (b) in patients with spondyloarthritides
(SpA): psoriatic arthritis (PsA), ankylosing spondylitis (AS)
and reactive arthritis (ReA); and control group. Box plots
represent the lower quartile, median and upper quartile. The
ends of the lines indicate the 10th and 90th centiles. ○ represent
extreme values, below the 10th or above 90th centile.  repre-
sents statistically significantly different compared to control
group, p  0.050.  represents statistically significantly
decreased compared to PsA and AS patients, p  0.050. 
Figure 1. Serum dipeptidyl peptidase IV (DPP IV) activity (a)
and mass concentration (b) in spondyloarthritides (SpA) and
rheumatoid arthritis (RA) patients and control group. Box
plots represent the lower quartile, median and upper quartile.
The ends of the lines indicate the 10th and 90th centiles.
○ represent extreme values, below the 10th or above 90th cen-
tile.  represent statistically significantly different compared
to control group, p  0.050. 
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or other biologically important fluids is unclear. Even 
though we demonstrated a reduced serum DPP IV activ-
ity, the immunodetection showed increased DPP IV 
concentration in both SpA and RA patients, when com-
pared to control group. Nevertheless, the decrease in 
DPP IV activity could not be explained by lower circu-
lating levels of DPP IV since we demonstrated an in-
creased serum DPP IV concentration. This discrepancy 
could partially be explained with the process of glyco-
sylation which causes structural alterations of DPP IV 
and could prevent its removal from the circulation. 
Although the most of published data indicate that DPP 
IV glycosylation is not a prerequisite for catalytic activi-
ty, homodimer formation or adenosine deaminase bind-
ing capacity, some reports show opposite evidence.20,21 
In line with the findings by Cuchacovich et al.22 it can 
be suggested that sialylation (a type of glycosylation) of 
specific sites of the enzyme might be involved as an 
underlying mechanism of the decreased DPP IV activity 
determined in serum of RA patients. Therefore, since 
we found that serum DPP IV activity and concentration 
in SpA patients were similar to those in RA patients, we 
speculate that such mechanism could also be present in 
SpA patients. However, further studies should be done 
in order to validate this suggestion.  
DPP IV as a serine peptidase is able to cleave nu-
merous biologically important molecules, including 
inflammatory mediators such as RANTES, SDF-1, 
vasoactive intestinal peptide and substance P.23 There-
fore, it can be suggested that changes of bioavailability 
of DPP IV substrate could influence the proliferation 
and recruitment of immune cells including the changing 
of the Th1/Th2 immune balance. Therefore, the signifi-
cance of the established reduced serum DPP IV activity 
is proposed. Interleukins and chemokines are released 
by different cells and their receptors are present on the 
surface of those cells. Hence, in the pathogenesis of 
inflammatory arthritis, each chemokine may induce 
different effects, depending on which receptor it bounds 
in a particular environment.24 It has been reported that 
SDF-1 and its receptor CXCR4 are supposed to play a 
crucial role in inflammatory cells recruitment. There is 
an established assumption that SDF-1 cleavage is 
mediated by DPP IV because N-terminally intact form 
was found in serum of CD26 deficient mice, whereas in 
serum of wild-type mice, SDF-1 is mostly converted 
to the inactive truncated form.18  
Apart through its enzymatic function, DPP IV may 
also potentially modulate the immune response by its 
role as a co-stimulatory molecule or its ability to inter-
act with the cytoplasmatic domain of CD45 and adeno-
sine deaminase.25 In SpA and RA, different cellular 
subsets are observed at sites of inflammation, including 
CD4+ and CD8+ T lymphocytes as well as B cells, mac
rophages and neutrophils.26–28 On the other hand, it has 
been reported that in patients with active RA the num-
ber of peripheral blood CD4+ T lymphocytes and mono-
cytes expressing DPP IV is increased.29,30 Thus, it could 
be suggested that the expression of CD26 on T lympho-
cytes in RA or SpA patients may interfere with activa-
tion and migration of these or some other inflammatory 
cells. Furthermore, it was shown that various competi-
tive, as well as uncompetitive DPP IV inhibitors were 
effective in alleviating inflammation, including experi-
mental models of RA.31 However, some of these inhibi-
tors showed anti-arthritic effects in DPP IV deficient 
animals, suggesting the potential importance of DPP IV-
like enzymes in the pathogenesis.32 Our results confirm 
the previously proposed theory that other proteins which 
posses DPP IV-like activity are active in serum and 
could be involved in the development of rheumatoid 
diseases. 
Taking in consideration the fact that inflammation 
is the major driver of disease activity, along with the 
evidence of the importance of DPP IV in modulation of 
immune response, we have tried to find a causal connec-
tion between them. Since we have observed no statisti-
cally significant difference in serum DPP IV activity 
and antigenic level between patients with active disease 
and those in remission in SpA and RA, it can be sug-




This study reveals new data about serum DPP IV activi-
ty and antigen level in adult SpA patients. A decreased 
serum DPP IV activity was found in SpA and RA pa-
tients compared to the control group, while the DPP IV 
concentration was increased. Moreover, our results 
showed no statistically significant difference in serum 
DPP IV activity or concentration between SpA and RA 
patients. The results of our study indicate that serum 
DPP IV activity could not be used as a specific non-
invasive clinical marker for differentiation of SpA dis-
eases, but could be potentially used as a non-specific 
inflammatory marker. Since we demonstrated changes 
in serum DPP IV activity and concentration in SpA 
patients and taking in consideration that non-selective 
DPP IV inhibitors showed potential anti-arthritic ef-
fects, this molecule could not be excluded as a potential 
mediator in inflammatory arthritis development.  
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